Abstract Objective: Developed a rapid, sensitive, and homogeneous immunoassay to characterize specific immunoglobulin E (sIgE) against HDM allergens in serum samples.  Methods: Initially, the reaction conditions were optimized, and the levels of sIgE specific to the major HDM components-Der p 1, Der p 2, and Der p 23-were measured using the Light-initiated Chemiluminescence Assay (LiCA) assay. The performance of this assay was evaluated in accordance with established clinical guidelines. Subsequently, we analyzed the distribution of these components among 90 children with various allergic diseases. Results: We established an optimal incubation time of 45 minutes. The coefficient of variation (CV) for repeatability ranged from 2.64% to 9.36%, while the intermediate precision varied from 5.77% to 9.89%. Component-resolved diagnosis (CRD) indicated that Der p 2 was the most frequently recognized componen (75.56%), followed by Der p 1 at 64.44%. The highest co-sensitization rate was observed between Der p 1 and Der p 2 (35.56%). Der p 23 sIgE levels were significantly elevated in patients with AA (P < 0.001). Additionally, a greater complexity in allergic symptoms was associated with an increased positive rate of Der p 23 (P = 0.007). Conclusion:We established an ssay for HDM component-sIgE using LiCA technology. Der p 2 was identified as the most frequently recognized allergen among the HDM components. Furthermore, our findings indicate a significant correlation between the complexity of allergic symptoms and elevated levels of Der p 23 sIgE.